Merck Accelerates U.S. Expansion and Rare Tumor Strategy with $3.9B Acquisition of SpringWorks Therapeutics

Stamford, CT, April 28, 2025 (Merck) -- Merck is acquiring SpringWorks Therapeutics for $3.9 billion in a deal that strengthens its position in rare oncology and expands its presence in the U.S. healthcare market. The acquisition aligns with Merck’s M&A strategy and is projected to boost revenue and earnings within two years of closing. SpringWorks’ innovative portfolio complements Merck’s existing assets and positions both companies for sustainable, long-term growth.

Read full article here.